BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Wu C, Liu Y, Wei D, Tao L, Yuan L, Jing T, Wang B. Gene Coexpression Network Characterizing Microenvironmental Heterogeneity and Intercellular Communication in Pancreatic Ductal Adenocarcinoma: Implications of Prognostic Significance and Therapeutic Target. Front Oncol 2022;12:840474. [DOI: 10.3389/fonc.2022.840474] [Reference Citation Analysis]
2 Xu J, Cheng K, Lin H, Han W, He T, Nie X, Sun Y, Qiuman S, Reheman Y, Chen Q. Characterization of the GATA Transcription Factor Family and Exploration of Their Relevance to Immune Infiltration and Tumor Microenvironment in Pancreatic Cancer. Int J Gen Med 2021;14:9083-101. [PMID: 34876843 DOI: 10.2147/IJGM.S342741] [Reference Citation Analysis]
3 [DOI: 10.1109/cvpr46437.2021.01353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hama Y, Tate E. High-dose planned adaptive intensity-modulated radiation therapy with simultaneous integrated boost for synchronous oligometastatic pancreatic cancer. Cancer Invest 2022;:1-13. [PMID: 35236196 DOI: 10.1080/07357907.2022.2049287] [Reference Citation Analysis]
5 Elshami M, Ahmed FA, Kakish H, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge J, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. HPB 2022. [DOI: 10.1016/j.hpb.2022.07.007] [Reference Citation Analysis]
6 Yang Z, Shi G, Zhang P. Development and Validation of Nomograms to Predict Overall Survival and Cancer-Specific Survival in Patients With Pancreatic Adenosquamous Carcinoma. Front Oncol 2022;12:831649. [PMID: 35330710 DOI: 10.3389/fonc.2022.831649] [Reference Citation Analysis]
7 Heger U, Hackert T. Can local ablative techniques replace surgery for locally advanced pancreatic cancer? J Gastrointest Oncol 2021;12:2536-46. [PMID: 34790414 DOI: 10.21037/jgo-20-379] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wu J, Sun S, Liao W, Chen E, Wang X, Song Y, Duan F, Deng W, Li S. LINC00460 promotes pancreatic cancer progression by sponging miR-491-5p. J Gene Med 2021;23:e3333. [PMID: 33789360 DOI: 10.1002/jgm.3333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 You W, Ke J, Chen Y, Cai Z, Huang ZP, Hu P, Wu X. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma. Front Immunol 2022;13:864244. [PMID: 35720314 DOI: 10.3389/fimmu.2022.864244] [Reference Citation Analysis]
10 Wang Y, Liang Y, Xu H, Zhang X, Mao T, Cui J, Yao J, Wang Y, Jiao F, Xiao X, Hu J, Xia Q, Zhang X, Wang X, Sun Y, Fu D, Shen L, Xu X, Xue J, Wang L. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discov 2021;7:36. [PMID: 34035226 DOI: 10.1038/s41421-021-00271-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Torres MB, Dixon MEB, Gusani NJ. Undertreatment of Pancreatic Cancer: The Intersection of Bias, Biology, and Geography. Surg Oncol Clin N Am 2022;31:43-54. [PMID: 34776063 DOI: 10.1016/j.soc.2021.07.006] [Reference Citation Analysis]
12 Terao T, Kumagi T, Hyodo I, Yokota T, Azemoto N, Miyata H, Kuroda T, Ohno Y, Tanaka Y, Shibata N, Imamura Y, Kanemitsu K, Miyake T, Koizumi M, Hiasa Y; Ehime Pancreato-Cholangiology (EPOCH) Study Group. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. Medicine (Baltimore) 2021;100:e27591. [PMID: 34713835 DOI: 10.1097/MD.0000000000027591] [Reference Citation Analysis]
13 Hogan G, Eckenberger J, Narayanen N, Walker SP, Claesson MJ, Corrigan M, O'Hanlon D, Tangney M. Biopsy bacterial signature can predict patient tissue malignancy. Sci Rep 2021;11:18535. [PMID: 34535726 DOI: 10.1038/s41598-021-98089-3] [Reference Citation Analysis]
14 Randazzo O, Papini F, Mantini G, Gregori A, Parrino B, Liu DSK, Cascioferro S, Carbone D, Peters GJ, Frampton AE, Garajova I, Giovannetti E. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. Cancers (Basel) 2020;12:E3206. [PMID: 33142664 DOI: 10.3390/cancers12113206] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Klimaszewska-Wiśniewska A, Buchholz K, Neska-Długosz I, Durślewicz J, Grzanka D, Zabrzyński J, Sopońska P, Grzanka A, Gagat M. Expression of Genomic Instability-Related Molecules: Cyclin F, RRM2 and SPDL1 and Their Prognostic Significance in Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:859. [PMID: 33670609 DOI: 10.3390/cancers13040859] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
16 Ji J, Jin D, Xu M, Jiao Y, Wu Y, Wu T, Lin R, Zheng W, Liu Z, Jiang F, Fan Y, Xiao M. AKR1B1 promotes pancreatic cancer metastasis by regulating lysosome-guided exosome secretion. Nano Res . [DOI: 10.1007/s12274-022-4167-z] [Reference Citation Analysis]
17 Zhang X, Zheng S, Hu C, Li G, Lin H, Xia R, Ye Y, He R, Li Z, Lin Q, Chen R, Zhou Q. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene 2022. [PMID: 35264742 DOI: 10.1038/s41388-022-02253-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang Z, Zhao W, Li Y, Li Y, Cheng H, Zheng L, Sun X, Liu H, Shao R. YOD1 serves as a potential prognostic biomarker for pancreatic cancer. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02616-9] [Reference Citation Analysis]
19 Partelli S, Sclafani F, Barbu ST, Beishon M, Bonomo P, Braz G, de Braud F, Brunner T, Cavestro GM, Crul M, Trill MD, Ferollà P, Herrmann K, Karamitopoulou E, Neuzillet C, Orsi F, Seppänen H, Torchio M, Valenti D, Zamboni G, Zins M, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treat Rev 2021;99:102208. [PMID: 34238640 DOI: 10.1016/j.ctrv.2021.102208] [Reference Citation Analysis]
20 Granchi C, Bononi G, Ferrisi R, Gori E, Mantini G, Glasmacher S, Poli G, Palazzolo S, Caligiuri I, Rizzolio F, Canzonieri V, Perin T, Gertsch J, Sodi A, Giovannetti E, Macchia M, Minutolo F, Tuccinardi T, Chicca A. Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. Eur J Med Chem 2021;209:112857. [PMID: 33045662 DOI: 10.1016/j.ejmech.2020.112857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Robinson CM, Talty A, Logue SE, Mnich K, Gorman AM, Samali A. An Emerging Role for the Unfolded Protein Response in Pancreatic Cancer. Cancers (Basel) 2021;13:E261. [PMID: 33445669 DOI: 10.3390/cancers13020261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Olson MT, Aguilar EN, Brooks CL, Isder CC, Muilenburg KM, Talmon GA, Ly QP, Carlson MA, Hollingsworth MA, Mohs AM. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer. Mol Pharm 2022. [PMID: 35640060 DOI: 10.1021/acs.molpharmaceut.2c00203] [Reference Citation Analysis]
23 Chang C, Li X, Cheng K, Cai Z, Xiong J, Lv W, Li R, Zhang P, Cao D. A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Oncologist 2022:oyac146. [PMID: 35930304 DOI: 10.1093/oncolo/oyac146] [Reference Citation Analysis]
24 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021;27:5851-89. [PMID: 34629806 DOI: 10.3748/wjg.v27.i35.5851] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
25 Ecker BL, Court CM, Janssen QP, Tao AJ, D'Angelica MI, Drebin JA, Gonen M, O'Reilly EM, Jarnagin WR, Wei AC; David M Rubenstein Center for Pancreatic Cancer Research Group at Memorial Sloan Kettering Cancer Center. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2022;235:342-9. [PMID: 35839413 DOI: 10.1097/XCS.0000000000000212] [Reference Citation Analysis]
26 Haksoyler V, Topkan E. Prognostic Utility of Prechemoradiotherapy Albumin-to-Alkaline Phosphatase Ratio in Unresectable Locally Advanced Pancreatic Carcinoma Patients. Gastroenterol Res Pract 2021;2021:6647145. [PMID: 33927759 DOI: 10.1155/2021/6647145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Topkan E, Selek U, Haksoyler V, Kucuk A, Durankus NK, Sezen D, Bolukbasi Y, Pehlivan B, Xie Z. Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers. International Journal of Clinical Practice 2022;2022:1-8. [DOI: 10.1155/2022/7473649] [Reference Citation Analysis]
28 Zhang LP, Ren H, Du YX, Wang CF. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World J Gastroenterol 2020; 26(46): 7382-7404 [PMID: 33362391 DOI: 10.3748/wjg.v26.i46.7382] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Wang X, Ye N, Xu C, Xiao C, Zhang Z, Deng Q, Li S, Li J, Li Z, Yang X. Hyperbaric oxygen regulates tumor mechanics and augments Abraxane and gemcitabine antitumor effects against pancreatic ductal adenocarcinoma by inhibiting cancer-associated fibroblasts. Nano Today 2022;44:101458. [DOI: 10.1016/j.nantod.2022.101458] [Reference Citation Analysis]
30 Iio S, Hozaka Y, Tanoue K, Idichi T, Fukuda K, Nakashima T, Yasudome R, Yamasaki Y, Kawasaki Y, Arigami T, Nakajo A, Higashi M, Mataki Y, Kurahara H, Ohtsuka T. Curative resection after chemotherapy and chemoradiotherapy for postoperative recurrence of pancreatic tail cancer in the abdominal wall: a case report. Surg Case Rep 2022;8:101. [PMID: 35585274 DOI: 10.1186/s40792-022-01452-3] [Reference Citation Analysis]
31 Huang J, Chen Z, Ding C, Lin S, Wan D, Ren K. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma. Front Oncol 2021;11:711402. [PMID: 34497764 DOI: 10.3389/fonc.2021.711402] [Reference Citation Analysis]
32 Yao J, Shi Y, Cao K, Lu L, Lu J, Song Q, Jin G, Xiao J, Hou Y, Zhang L. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imaging and tumor-vascular contact parsing. Med Image Anal 2021;73:102150. [PMID: 34303891 DOI: 10.1016/j.media.2021.102150] [Reference Citation Analysis]
33 Segaran N, Sandrasegaran K, Devine C, Wang MX, Shah C, Ganeshan D. Features of primary pancreatic lymphoma: A bi-institutional review with an emphasis on typical and atypical imaging features. World J Clin Oncol 2021; 12(9): 823-832 [PMID: 34631445 DOI: 10.5306/wjco.v12.i9.823] [Reference Citation Analysis]
34 Kim Y, Baek W. Caring experiences of family caregivers of patients with pancreatic cancer: an integrative literature review. Support Care Cancer 2022. [PMID: 34993653 DOI: 10.1007/s00520-021-06793-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Hayashi A, Hong J, Iacobuzio-Donahue CA. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 2021;18:469-81. [PMID: 34089011 DOI: 10.1038/s41575-021-00463-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 26.0] [Reference Citation Analysis]
36 Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero-Aguayo V, Jiménez-Vacas JM, Mafficini A, Sánchez-Frías ME, Cano MT, Abollo-Jiménez F, Marín-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sánchez L, Sánchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sánchez Á, Ibáñez-Costa A, Sainz B Jr, Luque RM, Castaño JP. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J Exp Clin Cancer Res 2021;40:382. [PMID: 34857016 DOI: 10.1186/s13046-021-02153-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ramya Devi KT, Karthick D, Saravanaraj KS, Jaganathan MK, Ghorai S, Hemdev SP. The roles of microRNA in pancreatic cancer progression. Cancer Invest 2022;:1-26. [PMID: 35333689 DOI: 10.1080/07357907.2022.2057526] [Reference Citation Analysis]
38 Zhang M, Ma S, Li X, Yu H, Tan Y, He J, Wei X, Ma J. Long non‑coding RNA CTBP1‑AS2 upregulates USP22 to promote pancreatic carcinoma progression by sponging miR‑141‑3p. Mol Med Rep 2022;25:86. [PMID: 35039872 DOI: 10.3892/mmr.2022.12602] [Reference Citation Analysis]
39 Yang Q, Mao Y, Xie H, Qin T, Mai Z, Cai Q, Wen H, Li Y, Zhang R, Liu L. Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis. JCO Precis Oncol 2022;6:e2100362. [PMID: 35319966 DOI: 10.1200/PO.21.00362] [Reference Citation Analysis]
40 Zhou Y, Gao S, Zhou B, Yuan S, Ren H, Wang Y, Guo X, Ren J, Chen Z, Hao J. Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma. Pancreatology 2021;21:763-70. [PMID: 33712388 DOI: 10.1016/j.pan.2021.02.016] [Reference Citation Analysis]
41 He J, Schulick RD, Del Chiaro M. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Ann Surg Oncol 2021;28:1514-20. [PMID: 33415556 DOI: 10.1245/s10434-020-09535-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wu W, Liu Q, Zhang J, Zhao Y. Survey on the current status of the diagnosis and treatment of pancreatic cancer in public tertiary hospitals in China: a cross-sectional questionnaire-based, observational study. Journal of Pancreatology 2021;4:164-9. [DOI: 10.1097/jp9.0000000000000079] [Reference Citation Analysis]
43 Gu X, Zhu Q, Tian G, Song W, Wang T, Wang A, Chen X, Qin S. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma. Cancer Med 2022. [PMID: 35619540 DOI: 10.1002/cam4.4683] [Reference Citation Analysis]
44 Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, Zhang G, Guo C, Zhang X, Chen W, Yadav DK, Bai X, Liang T. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun 2021;12:4536. [PMID: 34315872 DOI: 10.1038/s41467-021-24769-3] [Reference Citation Analysis]
45 Kim Y, Jee W, An E, Ko HM, Jung JH, Na Y, Jang H. Timosaponin A3 Inhibits Palmitate and Stearate through Suppression of SREBP-1 in Pancreatic Cancer. Pharmaceutics 2022;14:945. [DOI: 10.3390/pharmaceutics14050945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Waldenmaier M, Seibold T, Seufferlein T, Eiseler T. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Cancers (Basel) 2021;13:4844. [PMID: 34638330 DOI: 10.3390/cancers13194844] [Reference Citation Analysis]
47 Zhao G, Zhang T, Liu W, Edderkaoui M, Hu R, Li J, Pandol SJ, Fu X, Han YP. Sequestration of Intestinal Acidic Toxins by Cationic Resin Attenuates Pancreatic Cancer Progression through Promoting Autophagic Flux for YAP Degradation. Cancers (Basel) 2022;14:1407. [PMID: 35326559 DOI: 10.3390/cancers14061407] [Reference Citation Analysis]
48 Yue Y, Wu K, Qian W, Zhu Z, Zhang S, Zhang W, Zhang W, Wu S, Li L, Wu Z, Ma Q, Xie K, Wang Z. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Int J Biol Sci 2022;18:4245-59. [PMID: 35844783 DOI: 10.7150/ijbs.72204] [Reference Citation Analysis]
49 Wang D, Ge H, Tian M, Li C, Zhao L, Pei Q, Tan F, Li Y, Ling C, Güngör C. The Survival Effect of Radiotherapy on Stage IIB/III Pancreatic Cancer Undergone Surgery in Different Age and Tumor Site Groups: A Propensity Scores Matching Analysis Based on SEER Database. Front Oncol 2022;12:799930. [DOI: 10.3389/fonc.2022.799930] [Reference Citation Analysis]
50 Ren Y, Wang S, Wu B, Wang Z. Clinicopathological Features, Prognostic Factors and Survival in Patients With Pancreatic Cancer Bone Metastasis. Front Oncol 2022;12:759403. [PMID: 35223464 DOI: 10.3389/fonc.2022.759403] [Reference Citation Analysis]
51 Shen S, Wang Q, Wang X, Ding J, Chen F, Xiao Y, Qin T, Qian W, Li J, Ma Q, Ma J, Jakovljevic M. Nodal Enhances Perineural Invasion in Pancreatic Cancer by Promoting Tumor-Nerve Convergence. Journal of Healthcare Engineering 2022;2022:1-9. [DOI: 10.1155/2022/9658890] [Reference Citation Analysis]
52 He J, Lin X, Meng F, Zhao Y, Wang W, Zhang Y, Chai X, Zhang Y, Yu W, Yang J, Li G, Du X, Zhang H, Liu M, Lu W. A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis. Molecules 2022;27:1209. [DOI: 10.3390/molecules27041209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Lu J, Zhu D, Li L. Biological Functions and Molecular Mechanisms of MiR-608 in Cancer. Front Oncol 2022;12:870983. [PMID: 35387124 DOI: 10.3389/fonc.2022.870983] [Reference Citation Analysis]
54 Deng X, Fu X, Teng H, Fang L, Liang B, Zeng R, Chen L, Zou Y. E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1. J Transl Med 2021;19:332. [PMID: 34353343 DOI: 10.1186/s12967-021-03007-w] [Reference Citation Analysis]
55 Liang X, Peng J, Chen D, Tang L, Liu A, Fu Z, Shi L, Wang K, Shao C. Identification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysis. Gland Surg 2021;10:1104-17. [PMID: 33842254 DOI: 10.21037/gs-21-151] [Reference Citation Analysis]
56 Wakiya T, Ishido K, Yoshizawa T, Kanda T, Hakamada K. Roles of the nervous system in pancreatic cancer. Ann Gastroenterol Surg 2021;5:623-33. [PMID: 34585047 DOI: 10.1002/ags3.12459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kuang W, Wang X, Ding J, Li J, Ji M, Chen W, Wang L, Yang P. PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis. Front Immunol 2022;13:805311. [PMID: 35154122 DOI: 10.3389/fimmu.2022.805311] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zhang LP, Ren H, Du YX, Zheng XH, Zhang ZM, Wang CF. Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World J Gastrointest Surg 2021;13:279-302. [PMID: 33796216 DOI: 10.4240/wjgs.v13.i3.279] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Rivera D. Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer. Metabolites 2022;12:409. [DOI: 10.3390/metabo12050409] [Reference Citation Analysis]
60 Li ZY, Sun XY. Recent progress in SRC targeted therapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2021; 29(12): 621-627 [DOI: 10.11569/wcjd.v29.i12.621] [Reference Citation Analysis]
61 Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero-Aguayo V, Jiménez-Vacas JM, Mafficini A, Sánchez-Frías ME, Cano MT, Abollo-Jiménez F, Marín-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sánchez L, Sánchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sánchez Á, Ibáñez-Costa A, Sainz B Jr, Luque RM, Castaño JP. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J Exp Clin Cancer Res 2021;40:382. [PMID: 34857016 DOI: 10.1186/s13046-021-02153-9] [Reference Citation Analysis]
62 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
63 Li J, Kang R, Tang D. Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. Cancer Commun (Lond) 2021;41:642-60. [PMID: 34264020 DOI: 10.1002/cac2.12188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Malik RF, Hasanain A, Lafaro KJ, He J, Narang AK, Fishman EK, Zaheer A. Structured CT reporting of pancreatic ductal adenocarcinoma: impact on completeness of information and interdisciplinary communication for surgical planning. Abdom Radiol (NY) 2022;47:704-14. [PMID: 34800162 DOI: 10.1007/s00261-021-03353-9] [Reference Citation Analysis]
65 Yang R, Liang X, Wang H, Guo M, Shen H, Shi Y, Liu Q, Sun Y, Yang L, Zhan M. The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation. EBioMedicine 2021;63:103195. [PMID: 33418496 DOI: 10.1016/j.ebiom.2020.103195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
66 Xiong G, Pan S, Jin J, Wang X, He R, Peng F, Li X, Wang M, Zheng J, Zhu F, Qin R. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. Front Oncol 2021;11:765216. [PMID: 34760707 DOI: 10.3389/fonc.2021.765216] [Reference Citation Analysis]
67 Tan Z, Shi S, Xu J, Liu X, Lei Y, Zhang B, Hua J, Meng Q, Wang W, Yu X, Liang C. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Oncogene. [DOI: 10.1038/s41388-022-02306-w] [Reference Citation Analysis]
68 Ji X, Zhao Y, He C, Han S, Zhu X, Shen Z, Chen C, Chu X. Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. Front Oncol 2021;11:659987. [PMID: 34123818 DOI: 10.3389/fonc.2021.659987] [Reference Citation Analysis]
69 Garcia PL, Miller AL, Zeng L, van Waardenburg RCAM, Yang ES, Yoon KJ. The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. Front Oncol 2022;12:925718. [DOI: 10.3389/fonc.2022.925718] [Reference Citation Analysis]
70 Kratzer TB, Siegel RL, Miller KD, Sung H, Islami F, Jemal A. Progress Against Cancer Mortality 50 Years After Passage of the National Cancer Act. JAMA Oncol 2021. [PMID: 34762103 DOI: 10.1001/jamaoncol.2021.5668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
71 Tian W, Hao H, Chu M, Gong J, Li W, Fang Y, Zhang J, Zhang C, Huang Y, Pei F, Duan L. Berberine Suppresses Lung Metastasis of Cancer via Inhibiting Endothelial Transforming Growth Factor Beta Receptor 1. Front Pharmacol 2022;13:917827. [DOI: 10.3389/fphar.2022.917827] [Reference Citation Analysis]
72 Feng L, Wang J, Zhang J, Diao J, He L, Fu C, Liao H, Xu X, Gao Y, Zhou C. Comprehensive Analysis of E3 Ubiquitin Ligases Reveals Ring Finger Protein 223 as a Novel Oncogene Activated by KLF4 in Pancreatic Cancer. Front Cell Dev Biol 2021;9:738709. [PMID: 34722520 DOI: 10.3389/fcell.2021.738709] [Reference Citation Analysis]
73 Xiao Z, Li J, Yu Q, Zhou T, Duan J, Yang Z, Liu C, Xu F. An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma. Front Pharmacol 2021;12:778294. [PMID: 35002712 DOI: 10.3389/fphar.2021.778294] [Reference Citation Analysis]
74 Song W, Liu Z, Wang K, Tan K, Zhao A, Li X, Yuan Y, Yang Z. Pyroptosis-related genes regulate proliferation and invasion of pancreatic cancer and serve as the prognostic signature for modeling patient survival. Discov Oncol 2022;13:39. [PMID: 35633405 DOI: 10.1007/s12672-022-00495-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Deig CR, Sutton TL, Beneville B, Trone K, Stratton A, Gunesch AN, Liu AI, Alrohaibani A, Mohebnasab M, Bassale S, Grossblatt-Wait A, Keith D, Attia F, Gilbert EW, Lopez CD, Kardosh A, Chen EY, Bensch KG, Nabavizadeh N, Thomas CR, Mayo SC, Sheppard BC, Grossberg A. Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications. Cancers (Basel) 2022;14:609. [PMID: 35158877 DOI: 10.3390/cancers14030609] [Reference Citation Analysis]
76 Qian Y, Gong Y, Zou X, Liu Y, Chen Y, Wang R, Dai Z, Tasiheng Y, Lin X, Wang X, Luo G, Yu X, Cheng H, Liu C. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Oncogenesis 2022;11:35. [PMID: 35750693 DOI: 10.1038/s41389-022-00411-9] [Reference Citation Analysis]